PATH's Malaria Vaccine Initiative

What PATH's Malaria Vaccine Initiative does

PATH's Malaria Vaccine Initiative is a global health program within PATH, an international nonprofit organization headquartered in Seattle, WA, that advances the development and delivery of malaria vaccines to children in endemic regions. Founded in 1977, PATH has accumulated 25+ years of experience in malaria vaccine work, having supported the late-stage development of two WHO-recommended vaccines — RTS,S/AS01 (the world's first malaria vaccine) and R21/Matrix-M — for prevention of Plasmodium falciparum malaria in children living in endemic areas.

The initiative's core technology portfolio spans traditional recombinant vaccines, next-generation multistage vaccine candidates targeting circumsporozoite and blood-stage antigens, and monoclonal antibodies targeting different stages of the Plasmodium parasite's complex lifecycle. PATH has conducted 38 malaria vaccine clinical trials and supports 10+ national vaccine introductions across African countries including Uganda, DRC, Nigeria, and Kenya, providing on-the-ground technical assistance for maximizing uptake of the four-dose malaria vaccine schedule through routine immunization programs. Complementary services include health economics studies, budget impact analyses, and post-introduction research to optimize vaccine delivery.

As a nonprofit entity, the initiative operates on a grant-funded revenue model supported by donations, foundation grants (including GHIT Fund), government partnerships, and corporate contributions. There is no direct product sales revenue; instead, the organization functions as a development partner and technical advisor to national ministries of health and global health bodies such as WHO. Distribution occurs through national immunization programs in malaria-endemic African countries, with PATH providing implementation expertise rather than commercial distribution infrastructure. The initiative sits within PATH's broader Center for Vaccine Innovation and Access, which leverages PATH's nearly 50-year global health platform spanning Africa, Asia-Pacific, Americas, and Europe.

Name

PATH's Malaria Vaccine Initiative

Legal name

PATH

Website

https://malariavaccine.org

Company type

Private

Founded year

1977

Operating status

Operating

Headcount range

1–10 employees

Short description

PATH's Malaria Vaccine Initiative is a Seattle-based global health nonprofit program that develops and delivers WHO-recommended malaria vaccines (RTS,S/AS01 and R21/Matrix-M) for children in endemic African countries, providing technical assistance to national ministries of health for vaccine rollout and implementation.

Ownership category

akta.pro rank

Product category

Global Health / Malaria Vaccine Development & Delivery

NAICS

Scientific Research and Development Services (5417), Administration of Public Health Programs (92312)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

akta.pro secondary industries

Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE), Immunization & Vaccine Delivery Programs (BPADAIAB), Vaccine Policy, Advisory Committees & Program Governance (HLAJAHAJ), Immunization & Vaccination Programs Administration (BPAIAJAD)

Keywords

• Malaria vaccine development
• Global health nonprofit
• Vaccine implementation support
• Immunization program delivery
• Public health research

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Grant Funding and Donations: PATH operates as a global health nonprofit organization funded through grants, donations, and partnerships with governments, foundations, and corporations. The Malaria Vaccine Initiative is a program under PATH's Center for Vaccine Innovation and Access.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

PATH's Malaria Vaccine Initiative is a program under PATH's Center for Vaccine Innovation and Access that advances the development of WHO-recommended malaria vaccines (RTS,S/AS01 and R21/Matrix-M) and provides on-the-ground technical assistance to African ministries of health for rolling out the four-dose malaria vaccine schedule through national routine immunization programs. The initiative also conducts health economics studies, runs 38 malaria vaccine clinical trials, and advances next-generation vaccine candidates and monoclonal antibodies targeting different stages of the Plasmodium parasite lifecycle.

Product overview

PATH's Malaria Vaccine Initiative operates as a comprehensive vaccine development and delivery program within the Center for Vaccine Innovation and Access. The initiative encompasses two WHO-recommended malaria vaccines (RTS,S/AS01 and R21/Matrix-M), along with implementation support services for African countries rolling out these vaccines. The portfolio includes health economics studies to inform country decisions, post-introduction research to optimize current vaccines, and advancing next-generation vaccine candidates and monoclonal antibodies targeting the Plasmodium parasite lifecycle.

Differentiator

Problem solved

Functional benefit

Brands

• RTS,S/AS01: A malaria vaccine recommended by WHO for prevention of Plasmodium falciparum malaria in children living in endemic areas.
• R21/Matrix-M

Products and services

• RTS,S/AS01 Malaria Vaccine The world's first malaria vaccine, recommended by WHO for prevention of Plasmodium falciparum malaria in children living in endemic areas. PATH advanced this vaccine through late-stage development.
• R21/Matrix-M Malaria Vaccine WHO-recommended malaria vaccine for prevention of Plasmodium falciparum malaria in children living in endemic areas, used alongside RTS,S as part of national immunization programs.
• Malaria Vaccine Implementation Support Technical assistance provided to national ministries of health for on-the-ground support in maximizing uptake of the four-dose malaria vaccine schedule in African countries, integrated with routine immunization programs.
• Health Economics Studies Economic studies to help countries make informed decisions about immunization, including retrospective cost studies of malaria vaccine introduction and prospective estimates of vaccine delivery costs.
• Next-Generation Malaria Vaccine Candidates Novel and improved vaccine tools for comprehensive malaria control programs, targeting different stages of the Plasmodium parasite lifecycle.
• Malaria Monoclonal Antibodies Monoclonal antibodies targeting different stages of the Plasmodium parasite's complex lifecycle for malaria prevention.

Quantifiable outcome

• 38 malaria vaccine clinical trials conducted by PATH
• +1 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO recommends the programmatic use of RTS,S/AS01 and R21/Matrix-M vaccines for malaria prevention. PATH works with WHO to support country-level implementation of these recommended vaccines.
• National Ministries of Health (African Countries)coreStrategic or Co-development PartnerPATH works hand in hand with national ministries of health in African countries to provide on-the-ground technical assistance for maximizing uptake of malaria vaccines through district and community-level engagement.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• UNICEF Supply Division: UNICEF procures and distributes vaccines on behalf of many of the same African countries where PATH supports introduction. Its procurement role makes it a critical operational peer in the malaria vaccine delivery ecosystem.
• Medicines for Malaria Venture (MMV): MMV is a product development partnership focused on malaria therapeutics, sharing PATH's nonprofit, grant-funded model and mission to advance new tools against malaria. Both organizations operate as global health PDPs with overlapping donor and partner networks.
• Gavi, the Vaccine Alliance: Gavi co-finances vaccine introductions in lower-income countries and is a natural counterparty for PATH's MVI; both organizations work together to fund and operationalize rollout of WHO-recommended vaccines like RTS,S and R21 in endemic African countries.

Broad incumbents

• GSK: GSK is the developer and manufacturer of the RTS,S/AS01 malaria vaccine that PATH advanced through late-stage development. As the product owner, GSK is a critical partner and a broad incumbent in vaccines that overlaps with PATH's MVI focus area.
• World Health Organization (WHO): WHO sets vaccine policy and recommendations that PATH's MVI program operationalizes. As the global normative body for malaria vaccine guidance, WHO is both a core partner and a broader incumbent shaping the program landscape.
• Bill & Melinda Gates Foundation: The Gates Foundation is a major funder of PATH's malaria vaccine work and of global immunization broadly. As a top-tier philanthropic incumbent in global health, it shares PATH's mission focus and frequently co-funds the same programs.
• Serum Institute of India: Serum Institute manufactures the R21/Matrix-M malaria vaccine recommended by WHO alongside RTS,S. As a major vaccine manufacturer supplying African immunization programs, it is directly relevant to PATH's MVI delivery work.

Emerging players

• Coalition for Epidemic Preparedness Innovations (CEPI): CEPI funds and coordinates vaccine development against emerging infectious threats, operating a similar end-to-end model from R&D through access. While malaria is not its central focus, CEPI shares PATH's PPP structure and clinical development capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xbsky.app/profile/path.org
• YouTubeyoutube.com/user/globalhealthcatalyst
• Facebookfacebook.com/PATHglobalhealth
• LinkedInlinkedin.com/company/path's-malaria-vaccine-initiative
• Instagraminstagram.com/pathglobalhealth

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PATH's Malaria Vaccine Initiative